Louisana Taxotere Trial
Louisiana Taxotere Trial set for September 2018July 17, 2017
The state of Louisiana has set September 2018 as the start date for the first case in the Multi-District Litigation (MDL) case against drug manufacturer Sanofi for its breast cancer drug Taxotere, which is alleged to caused permanent hair loss in women who take it.
At issue is whether Sanofi knew of the hair-loss side effect of Taxotere, and whether the company sufficient informed doctors and their patients about that particular risk. In many cancer treatment programs, hair loss is temporary; the suits allege that, in the case of Taxotere treatment programs, the hair loss is irreversible.
Central to the suit is that another, equivalent drug – called Taxol – was and is available for the treatment of breast cancer, and that, while Taxotere has been linked with permanent hair loss, Taxol is linked only with temporary hair loss.
Taxotere, a chemotherapy drug, was approved by the U.S. Food and Drug Administration (FDA) as a cancer treatment in 1996. It is currently the subject of several lawsuits in multiple states.
As of the middle of May 2017, more than 1100 individual cases had been included in the MDL.
If you’ve undergone chemotherapy treatment for breast cancer, and have experienced permanent hair loss, you may be eligible to be part of a lawsuit against the makers of Taxotere. Contact TheLawFirm.com to learn about how to participate in a suit.
TheLawFirm.com’s award winning lawyers have been featured in over 50 radio and television interviews including:
Real lawyers, real results!
no recovery, no fee!